by | May 26, 2024 | Publications
Int J Infect Dis. 2024 May 23:107108. doi: 10.1016/j.ijid.2024.107108. Online ahead of print. ABSTRACT OBJECTIVES: Daratumumab-treated myeloma patients may face increased seasonal influenza risk due to weakened post-vaccination immune responses, especially with...
by | May 25, 2024 | Publications
Biomedicines. 2024 May 4;12(5):1014. doi: 10.3390/biomedicines12051014. ABSTRACT (1) Background: The introduction of novel therapies has led to a considerable evolution in the management of Multiple Myeloma, and chromosomal abnormalities predict the success of...
by | May 25, 2024 | Publications
Biomedicines. 2024 May 8;12(5):1032. doi: 10.3390/biomedicines12051032. ABSTRACT Kidney involvement with resulting kidney failure leads to increased mortality in patients with multiple myeloma (MM). Cast nephropathy (CN), in particular, if left untreated, quickly...
by | May 25, 2024 | Publications
Int J Mol Sci. 2024 May 10;25(10):5208. doi: 10.3390/ijms25105208. ABSTRACT Over the last decades, the survival of multiple myeloma (MM) patients has considerably improved. However, despite the availability of new treatments, most patients still relapse and become...
by | May 25, 2024 | Publications
Int J Mol Sci. 2024 May 12;25(10):5269. doi: 10.3390/ijms25105269. ABSTRACT Multiple myeloma (MM) is the second most common hematological malignancy, which remains incurable despite recent advances in treatment strategies. Like other forms of cancer, MM is...
by | May 25, 2024 | Publications
Cancers (Basel). 2024 May 13;16(10):1854. doi: 10.3390/cancers16101854. ABSTRACT Daratumumab is being increasingly integrated into first-line multiple myeloma (MM) induction regimens, leading to improved response depth and longer progression-free survival. Autologous...
